MX2021015057A - Anticuerpos anti-talen y usos de los mismos. - Google Patents

Anticuerpos anti-talen y usos de los mismos.

Info

Publication number
MX2021015057A
MX2021015057A MX2021015057A MX2021015057A MX2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A MX 2021015057 A MX2021015057 A MX 2021015057A
Authority
MX
Mexico
Prior art keywords
antibodies
talen
talens
things
sample
Prior art date
Application number
MX2021015057A
Other languages
English (en)
Inventor
Barbra Johnson Sasu
Thomas Charles Pertel
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of MX2021015057A publication Critical patent/MX2021015057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, anticuerpos para detectar las nucleasas TALEN y/o FokI en una muestra y métodos para usarlos.
MX2021015057A 2019-06-13 2020-06-12 Anticuerpos anti-talen y usos de los mismos. MX2021015057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861214P 2019-06-13 2019-06-13
PCT/US2020/037589 WO2020252381A2 (en) 2019-06-13 2020-06-12 Anti-talen antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021015057A true MX2021015057A (es) 2022-01-18

Family

ID=73745889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015057A MX2021015057A (es) 2019-06-13 2020-06-12 Anticuerpos anti-talen y usos de los mismos.

Country Status (12)

Country Link
US (2) US11781248B2 (es)
EP (1) EP3983435A4 (es)
JP (1) JP2022536341A (es)
KR (1) KR20220020905A (es)
CN (1) CN113993891A (es)
AU (1) AU2020291939A1 (es)
BR (1) BR112021025029A2 (es)
CA (1) CA3138501A1 (es)
IL (1) IL288807A (es)
MX (1) MX2021015057A (es)
SG (1) SG11202112553WA (es)
WO (1) WO2020252381A2 (es)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR101419729B1 (ko) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2011101328A2 (en) * 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
EP3567051A1 (en) * 2013-04-15 2019-11-13 Janssen Vaccines & Prevention B.V. Human antibodies binding to rsv g protein
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
JP6606088B2 (ja) * 2014-02-24 2019-11-13 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
JP6744292B2 (ja) * 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
FR3034420A1 (fr) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303

Also Published As

Publication number Publication date
CN113993891A (zh) 2022-01-28
SG11202112553WA (en) 2021-12-30
WO2020252381A2 (en) 2020-12-17
KR20220020905A (ko) 2022-02-21
BR112021025029A2 (pt) 2022-01-25
US20240003056A1 (en) 2024-01-04
US11781248B2 (en) 2023-10-10
EP3983435A2 (en) 2022-04-20
EP3983435A4 (en) 2023-03-08
JP2022536341A (ja) 2022-08-15
IL288807A (en) 2022-02-01
WO2020252381A3 (en) 2021-03-11
AU2020291939A1 (en) 2021-12-02
US20200392252A1 (en) 2020-12-17
CA3138501A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
PH12020551028A1 (en) Methods, kits and apparatus for expanding a population of cells
ZA202206078B (en) Anti-cd3 antibodies and methods of use
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
CR20190574A (es) Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
WO2016196765A3 (en) Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
EP4235179A3 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
WO2019213606A3 (en) Solid forms of cerdulatinib
AU2018279738A1 (en) Methods of enhancing development of renal organoids and methods of using the same
MX2021015057A (es) Anticuerpos anti-talen y usos de los mismos.
EP4317980A3 (en) Methods of assessing antibody-drug conjugates
WO2019012481A3 (en) G-QUADRUPLEXES DIVIDED FOR CAPTURE AND DETECTION OF NUCLEIC ACIDS
WO2015051166A3 (en) Use of cox-3 binding molecules for modulating autophagy
WO2016111538A3 (ko) 성호르몬 검출용 시약 키트 및 이를 이용한 성호르몬 검출 방법
MX2016010788A (es) Metodos y sistemas para la deteccion rapida de microorganismos utilizando anticuerpos libres.
MX2021014335A (es) Metodos para detectar un nivel de h. pylori en una muestra fecal.
WO2022090801A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment